Laboratory products
Monoclonal antibodies, or mAbs, are antibodies that have been developed and produced from the same identical parent immune cell. As such, they can be developed and honed by scientists to target and identify specific cells and antigens and to work as antibodies in tandem with the human immune system against them.
As research into mAbs and their potential uses is ongoing, scientists hope to augment their knowledge of the antibodies and increase their usefulness. For more information on such research, this article provides a helpful insight. For now, though, here are ten applications of mAbs, some proven and some potential.
Once mAbs are produced for a specific substance, they can be then used to test for the presence of that substance in a vessel. This can include toxins, drugs or hormones.
MAbs that have been developed to detect human chorionic gonadotropin (HCG) are now present in pregnancy test kits.
An imaging technique used to detect the presence of cancerous or cancer-specific cells has been developed deploying radio-labelled antibodies, which can be produced as mAbs.
Similar to RID, RIT uses mAbs to specifically target antigen cells that are associated with tumours, and then blast these with a lethal dose of radiation, whilst minimising the level of radiation absorbed by normal cells.
Many different drugs are being developed in clinical trials with the ultimate hope of being able to treat various strains of cancer. In fact, some of these are already on the market. In 1997, a drug named Ritoxin was approved by the FDA for commercial use which is based on mAb technology.
Doctors hope that with further research into mAbs and an increased knowledge of their properties, treatments will become available for diseases previously thought to be incurable, such as AIDS.
MAbs can now be used to identify strains of a single pathogen, for example neisseria gonorrhoeae.
Scientists can use mAbs to first identify and then track certain cells or molecules in a living thing, and determine its function. For example, scientists at the University of Oregon are using such practices to determine which proteins are responsible for differentiation amongst cells in the respiratory system.
A certain mAb named OKT3 (developed as an antibody to the T3 antigen) is able to be used to alleviate the effects and likelihood of organ rejection when transplanting new organs into a subject.
Anti-rhesus antiserum is becoming increasingly hard to find, and the UK Blood Products laboratory has been researching the possibility of substituting mAb rhesus immunisation, with a view to ultimately replacing the serum.